Several in vitro studies have shown that tumor cells which are sensitive to EGFR-targeted therapy, will also respond to the inhibitory effects of a number of cytotoxic drugs, which differ in their mechanism of action [14,15]. This evidence concerns the gene EGFR and neoplasm.